Vimarsana
Biggest News Aggregation in the World

Page 2 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Gossamer sells rights to drug it hopes can rival a new Merck therapy - Vimarsana News

Gossamer sells rights to drug it hopes can rival a new Merck therapy

BioPharma

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT - Vimarsana News

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...

Betty Larson joins Merck as chief HR officer - Vimarsana News

Betty Larson joins Merck as chief HR officer

Merck has tapped Betty Larson as EVP, chief human resources officer. Larson brings 20 years of healthcare experience to the role.

FDA approves Merck's drug to treat rare, deadly lung disease - Vimarsana News

FDA approves Merck's drug to treat rare, deadly lung disease

Merck bought the company developing the drug for $11.5 billion in 2021

Source: qz.com
FDA approves Merck's drug for rare, deadly lung condition - Vimarsana News

FDA approves Merck's drug for rare, deadly lung condition

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the...